Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study

OBJECTIVE: To assess the safety and biological activity of rozibafusp alfa, a first‐in‐class bispecific antibody–peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid arthritis (RA). METHODS: This phase 1b, double‐blind, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuqayyas, Lubna, Cheng, Laurence E., Teixeira dos Santos, Marcia, Sullivan, Barbara A., Ruiz‐Santiago, Norma, Wang, Hui, Zhou, Yanchen, Chindalore, Vishala, Cohen, Stanley, Kivitz, Alan J., Posch, Maximilian G., Parnes, Jane R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555197/
https://www.ncbi.nlm.nih.gov/pubmed/35899378
http://dx.doi.org/10.1002/acr2.11487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555197/
https://www.ncbi.nlm.nih.gov/pubmed/35899378
http://dx.doi.org/10.1002/acr2.11487

Ejemplares similares